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Abstract
Background: Gait and mobility impairments affect the quality of life (QoL) of patients with progressive multiple
sclerosis (MS). Robot-assisted gait training (RAGT) is an effective rehabilitative treatment but evidence of its superiority
compared to other options is lacking. Furthermore, the response to rehabilitation is multidimensional, person-specific
and possibly involves functional reorganization processes. The aims of this study are: (1) to test the effectiveness on
gait speed, mobility, balance, fatigue and QoL of RAGT compared to conventional therapy (CT) in progressive MS and
(2) to explore changes of clinical and circulating biomarkers of neural plasticity.
Methods: This will be a parallel-group, randomized controlled trial design with the assessor blinded to the group allocation
of participants. Ninety-eight (49 per arm) progressive MS patients (EDSS scale 6–7) will be randomly assigned to receive
twelve 2-h training sessions over a 4-week period (three sessions/week) of either: (1) RAGT intervention on a robotic-driven
gait orthosis (Lokomat, Hocoma, Switzerland). The training parameters (torque of the knee and hip drives, treadmill speed,
body weight support) are set during the first session and progressively adjusted during training progression or (2) individual
conventional physiotherapy focusing on over-ground walking training performed with the habitual walking device. The
same assessors will perform outcome measurements at four time points: baseline (before the first intervention session);
intermediate (after six training sessions); end of treatment (after the completion of 12 sessions); and follow-up (after
3 months from the end of the training program). The primary outcome is gait speed, assessed by the Timed 25-Foot
Walk Test. We will also assess walking endurance, balance, depression, fatigue and QoL as well as instrumental
laboratory markers (muscle metabolism, cerebral venous hemodynamics, cortical activation) and circulating
laboratory markers (rare circulating cell populations pro and anti-inflammatory cytokines/chemokines, growth
factors, neurotrophic factors, coagulation factors, other plasma proteins suggested by transcriptomic analysis and
metabolic parameters).
Discussion: The RAGT training is expected to improve mobility compared to the active control intervention in progressive
MS. Unique to this study is the analysis of various potential markers of plasticity in relation with clinical outcomes.
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Background
Multiple sclerosis (MS) is a chronic inflammatory
disease causing widespread degeneration of the central
nervous system. The disease, with different features and
progression according to the clinical phenotype [1],
gradually results in severe neurological deficits [2] with
complex, variable and unpredictable patterns of
symptoms [2] including different motor deficits [1].
Locomotor disability and balance disorders affect
approximately 75% of persons with MS, with altered co-
ordination of posture and gait [3, 4], mobility problems
[5, 6], reduced walking competency [3] and increased
risk of falling [7]. In progressive MS, the high prevalence
of motor disorders and gait disabilities, the negative im-
pact on personal activities and quality of life (QoL), and
the limited effects of specific medications [8] make gait
rehabilitation a crucial part of the management. The aim
is to increase patients’ levels of activity and independ-
ence [9] and their QoL, even independent of symptom
regression [10, 11]. Gait disabilities showed improve-
ment following physical therapy [4, 12–14] and low-to-
moderate-intensity aerobic over-ground or treadmill
training, which represents a useful option for rehabi-
litation, also in combination with body weight support
[15–17]. To this end, a robot-driven gait orthosis was re-
cently developed, studied and considered a feasible and
effective therapeutic option in MS subjects with severe
walking disabilities. Robot-assisted gait training (RAGT)
allows a more effective support of walking movements
and imitation of a nearly normal gait pattern during
treadmill training at a higher speed, with improvements
in walking distance, velocity and knee extensor strength
compared to conventional therapy [18, 19]. Several
studies have tested in samples of MS patients the effects of
interventions, such as treadmill training [4], bodyweight-
supported training on a treadmill [20, 21], RAGT [18, 19,
22–26], or both treatments combined within a single
session [27], reporting small but positive effects on func-
tional status [4, 18–20, 23–26] or QoL [10, 21]. Recently,
improvements were reported in the 6-min Walking Test
and in the balance domain after RAGT [25] but not in gait
speed measured by the 10-m Walk Test [26]. Unfortunately
these studies, using different devices and training protocols
(12 to 15 sessions over 3–6 weeks), including heteroge-
neous MS subgroups with a limited number of subjects
and a wide range of gait disabilities (Expanded Disability
Status Scale, EDSS 3–7.5), failed to offer an exhaustive evi-
dence of the superiority of RAGT over other specific gait
trainings, so larger trials are necessary [28]. Otherwise, this
might be partially explained by the fact that the rehabilita-
tion process in MS subjects is complex and person-specific
[28] as the response to treatments regarding neuronal plas-
ticity is highly individual. Functional recovery in MS is
achieved by repair of damage through remyelination, with
resolution of inflammation and functional reorganization.
Evidence from brain systems supports an adaptive role for
neuroplastic changes in MS despite its widespread path-
ology. Specifically, it may limit the negative effects of MS
on behavior [29–32] and differs between patients and
various disease types, with lower response according to pa-
tient age and disease duration [33, 34]. Moreover, different
rehabilitation treatments might switch on different adaptive
response. High-intensity interventions might be more ef-
fective on neural reorganization and motor recovery involv-
ing synaptic transmission and formation of novel synapses,
cortical reorganization and induction of neurogenesis lim-
ited to the site of injury or involving distant healthy brain
regions [35]. The effects of neuroplasticity-based technolo-
gies and interventions, virtually beneficial for functional re-
covery, have been poorly tested so far. Different tools, such
as positron emission tomography and functional magnetic
resonance imaging, could be appropriate to evaluate such
recovery-related processes. Several studies have employed
these techniques, revealing that in MS patients a decreased
hemispheric lateralization [32] and an increasingly bilateral
activation, even for simple motor tasks involving higher-
control sensorimotor areas, were observed [36, 37]. Other
noninvasive, reliable and less expensive measurements,
such as transcranial magnetic stimulation and near-infrared
spectroscopy (NIRS), could also be useful. In a NIRS-based
study the coherence, considered a potentially useful marker
in disorders with white matter damage or axonal loss, was
found to be similar in MS subjects and controls in the rest-
ing phase, but significantly decreased during motor tasks
[38]. Moreover, relevant information to identify patterns of
recovery in MS patients could be added by the measure-
ment of molecular regulators of neuronal or vascular plasti-
city. These biomarkers derived from blood tests include
circulating cell subsets and soluble factors measurable in
plasma. Previous studies involving MS subjects showed that
the N-acetylaspartate concentration correlated with an
increased lateralization index; neurotrophins that regulate
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neural plasticity, such as brain-derived neurotrophic factor
(BDNF) [39], were found in lower concentrations compared
to healthy subjects [40]. Furthermore, inflammatory cyto-
kines, such as interleukin-1β, negatively interact with BDNF
and amyloid-β has been observed in multifocal MS lesions
[41, 42]. Finally, growth factors participate in neural cell
survival and tissue repair processes [43–45] and, in particu-
lar, platelet-derived growth factor decreases with disease
duration, being low in primary progressive MS patients [46]
while incomplete glucose oxidation by glycolysis and mito-
chondria results in increased oxidative stress that promotes
lesion progression rather to repair [47–49]. Also, distur-
bances of the hemostatic mechanisms, which are closely
and reciprocally related to inflammation, are relevant for
neurological disorders, in particular procoagulant factors
and receptors, as well as main anticoagulant proteins
endowed with anti-inflammatory activities, that exert cyto-
protective effects and favor endothelial barrier stabilization,
neurogenesis and angiogenesis [50]. Lastly, besides soluble
factors, growing evidence advances the concept that stem
cells can modulate nervous system action as well as the
dysregulation of inflammatory responses and immune self-
tolerance has to be considered a key element in the auto-
reactive immune response in MS. To this end, circulating
stem/progenitor cells capable of homing in on neovascular-
ization sites [51], and regulatory T-cells (Treg) have
emerged as crucial players in the pathogenic scenario of
autoimmune inflammation with a role in their modulation
by pharmacological and rehabilitation therapy.
Aims
The primary objective of the study is the verification of
the starting hypothesis that RAGT could have greater
benefit, compared with conventional therapy alone, in
gait speed improvement as assessed by the Timed 25-Foot
Walk Test (T25FW).
Secondarily, the study aims to determine whether
fatigue, QoL, balance and mobility are improved by
RAGT. Finally, the study aims to collect information on
whether RAGT or the active control group (CT) influ-
ence markers of plasticity, including clinical and circulating
biomarkers, and if these modifications are correlated with
clinical outcome. The ultimate goal is to draw tailored
rehabilitation strategies capable of bypassing the person-
specific treatment response in MS patients.
Methods
Study design and setting
This study is a parallel-assignment, single-blinded, ran-
domized controlled trial with the assessor blinded to the
group allocation of participants (Fig. 1). Participants meet-
ing the inclusion criteria and who provide written
informed consent will be randomly assigned to one of the
two treatments: the RAGT or the CT group. This study
was approved by the Ethics Committee of Ferrara
province with approval number 101-2012. This protocol is
reported following the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guide-
lines [52]. A populated SPIRIT Checklist is available as
additional file (Additional file 1). Subjects will be
recruited using several methods, including the identifi-
cation of MS patients who are referred to the Rehabili-
tation Clinics of the Operative Unit of Physical and
Rehabilitation Medicine of Ferrara University Hospital
and from the Centro Malattie Rare e Neuroimmunitarie,
IRCCS Neuroscienze Bellaria, Bologna. All the interven-
tions scheduled, as well as the outcome measure assess-
ment, will be performed at the Operative Unit of Physical
and Rehabilitation Medicine of Ferrara University Hospital.
Selection criteria and recruitment of participants
Patients affected by primary and secondary progressive
MS [53] will be invited to participate if they meet the
following inclusion criteria:
 Men and women, aged 18 to 65 years
 Severe gait impairments, defined by an EDSS score
[54] ranging from 6 to 7
 Ability to perform the T25FW
 Lack of MS worsening in the 3 months just before
the intervention period
 Cognitive functioning to give informed consent
identified by a Mini Mental Status Examination
(MMSE) score ≥24/30 [55]
Exclusion criteria include:
 Neurological conditions in addition to MS that may
affect motor function and other medical conditions
likely to interfere with the ability to complete the
study protocol safely, independently from the group
assignment
 Considerable muscle spasticity, defined by a
Modified Ashworth Scale (MAS) [56] score >3 or
contractures that may limit range of motion or
function of hip, knee or ankle flexors/extensors
 Relapsing of MS-related conditions or changes in
drug therapy (both disease-modifying or symptomatic
therapies) or any other confounding factor during
the study
 Rehabilitation treatments or botulinum toxin
injections during the 3 months preceding the start
of the study
During the first meeting with potential participants the
physician will ask them if they are interested in taking part
in the study; if they are, the physician will address them to
a specific screening visit to verify compliance with the
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inclusion criteria. If compliance is satisfactory, the study
physician responsible for inclusion will deliver the letter
explaining the study, as well the Consent Form, to the
potential participant, and will encourage them to ask any
question. After at least 3 days, the patients will be con-
tacted by phone and asked about their decision; in case of
voluntary participation, patients will be given an appoint-
ment where they will consign the informed consent and
where a physiotherapist will perform the baseline outcome
measures; if the patients have not yet decided, they will be
given adequate time to consider their participation;
whereas if the subjects decline participation, they will be
thanked for their consideration. According to the Consoli-
date Standards of Reporting Trials (CONSORT) guide-
lines [57], the total number of screened subjects who are
ineligible (and the reasons for their ineligibility), or who
are not willing to participate in the study, will be tracked.
To optimize recruitment, all members of the rehabilitation
unit of the hospital, including physicians, physiotherapists
and nurses, will be contacted weekly by the research co-
ordinator to identify possible participants. Moreover, the
research coordinator will participate in the rehabilitation
team meetings to check the availability of potentially eli-
gible patients. Information on the study procedures will
also be given to the MS support groups.
Randomization and blinding
After the collection of the informed consent and of the
baseline data, the physician responsible for the enrollment
will create the allocation sequence, on a personal
password-protected computer. The password to log into
the allocation list will be given only to the research coord-
inator, to the physician who created it, and to the adminis-
trator responsible of randomization. Then patients will be
randomized to one of the two groups by the external
administrator not involved in the trial to prevent selection
bias through a computerized randomization stratification
approach. Participants will be stratified by their degree of
impairment (EDSS score) to obtain a balance between
groups regarding the baseline physical capacity. The
randomization scheme (1:1 ratio) will be set up in per-
muted blocks of 4 to ensure a similar number of partici-
pants between groups. Finally, the subjects will be assigned
to one of the two treatment groups: RAGT (experimental
group) or CT (active control group). The participants can-
not be blinded to the two interventions as the two training
protocols were detailed in the informative form for the
patients given during the screening visit. Once randomized,
patients cannot change the treatment assigned for any rea-
son (e.g., participant request), but in case any medical con-
ditions derived from that specific treatment develop, the
Fig. 1 Design of the RAGTIME Study. EDSS expanded disability status scale, RAGT robot-assisted gait training
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training will be immediately suspended. Outcome measure
assessors who have to remain blind to group allocation will
not have access to the randomization list. Unblinding will
not be permissible for these researchers. All outcome data
will be recorded on two different electronic spreadsheets
by two blinded researchers involved in the trial, and the
accuracy of the data will be checked by the research
coordinator for all the outcome measures. The privacy of
the participants and their personal medical records will be
guaranteed by treating the data according to the Italian
Law n. 196/2003, to the “Safe Harbor Act” (2000/520/CE)
and to the “European Union Data Protection Directive
(95/46/EC 24 October 1995).”
Intervention
Participants in both intervention groups will receive
twelve 2-h training sessions over a 4-week period, result-
ing in a three sessions/week pattern. A pragmatic window
will be set to ensure for each participant the execution of
all 12 sessions in a maximum of 5 weeks, to accommodate
possible withdrawal of one or more sessions (e.g., intercur-
rent illness, sudden family problems, etc.). Patients who
miss more than three consecutive training sessions will be
dropped out from the study. If a participant misses a train-
ing session, the physiotherapist will inform the research
coordinator and will contact the patient by phone, to
determine reasons for missing and to motivate them to
take part to the next scheduled training session.
The first training hour will consist of the specific training
scheduled for each group (gait training), whereas the
second training hour will be common to both groups.
In detail, an experienced physiotherapist will perform
lower-limb and core stretching exercises to increase
muscle flexibility as well as strengthening exercise for
the lower limbs. The second training hour will be car-
ried out over the entire duration of the study by the
same physiotherapist, treating two participants contem-
poraneously, to ensure the same exercises for all patients
to avoid possible confounding factors and bias during the
results interpretation.
RAGT experimental group
Patients included in this group will perform RAGT on the
Lokomat treadmill (Hocoma AG, Volketswil, Switzerland).
During these sessions subjects will wear a harness attached
to a system to provide body weight support and they will
walk on the treadmill with the help of a robotic-driven gait
orthosis. The legs are guided according to a physiological
gait pattern. The torque of the knee and hip drives can be
adjusted from 100 to 0% for one or both legs. The speed of
the treadmill can be adjusted from 0 km/h to approxi-
mately 3 km/h and body weight support from 0 to 100%.
During the first session, these training parameters will be
set according to subject characteristics and demand level.
As training progresses, adjustments in the assistance pro-
vided by the driven gait orthosis (guidance), the amount of
body weight support and treadmill speed will be performed.
Training sessions will last for an hour with 30-min of real
walking time because subject setup in the device takes
approximately 30 min. At the end of each session the total
meters walked, the average walking speed and the percent-
age of body weight support from 0 to 100% will be tracked.
Active control group (CT)
Patients included in the CT will focus their efforts on gait
training. During the 1-h individual physiotherapy sessions,
patients will perform assisted over-ground walking for a
total of around 40 min, inserted between a 10-min warm-
up and cool-down period. The patient will be encouraged
by the same experienced physiotherapist to walk back and
forth on an 80-m indoor flat corridor with their habitual
walking device (crutches, rollator). Every patient will be
asked to walk without stop until reaching an effort corre-
sponding to a value of 8 out of 10 of the Borg Rating of
Perceived Exertion Scale [58]. When that given intensity
has been reached, the patients will be allowed to rest sit-
ting on a chair; after a suitable rest period, sufficient for
the patient to return to values of 1/10 of the scale, the
training will restart following the procedures previously
reported. At the end of each session, the total meters
walked, as well as the effective walking time, will be re-
corded on a properly developed module.
Concomitant care and recommendations
During the 4-week period of in-hospital training, patients
will be asked not to undertake other physiotherapist treat-
ments. Moreover, patients will be asked to wear the same
shoes and orthosis during all the testing and training
sessions.
Intervention fidelity and monitoring of adverse events
Before the beginning of the study, treatment physiothera-
pists will be trained by a member of the research team
with a high level of experience in RAGT and CT training
of MS patients. Physiotherapists will be provided with 1:1
guidance focused on the treatment’s characteristics and
peculiarities, and their ability to complete training sessions
will be verified. When the study begins, to each physio-
therapist will be given the module to record the specific
training administered to each participant. During the
whole duration of the study, the members of the research
team and research coordinator will randomly visit training
sessions, to ensure that the scheduled intervention is
being performed accurately and with high adherence to
the protocol proposed. Any adverse unpredictable event
will be recorded in the registry of each patient and the
electronic database of the study, and managed according
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to the policies of the hospital, with referral for appropriate
medical follow-up.
Outcome assessment and data collection
Outcome measurements will be evaluated at the Opera-
tive Unit of Physical and Rehabilitation Medicine of
Ferrara University Hospital by the same blinded asses-
sors at the four time points (Fig. 1): (a) baseline (prior to
the first intervention session, T0), (b) intermediate (after
six training sessions, T1), (c) end of treatment (after the
completion of 12 sessions, T2) and (d) follow-up (after
3 months from the end of training program, T3). Before
the last outcome assessment, a blinded physiotherapist
will contact each participant to remind them to attend
the measurements sessions. A summary of the measures
to be collected is reported in Table 1. A physician mem-
ber of the research team involved in the subject enroll-
ment will administer the MMSE and all the other
clinical measures (EDSS, MAS) to determine eligibility
for each patient. Moreover, the person responsible for
the participant selection will record the general
demographic information (age, gender), comorbidities
and medical history.
Primary outcome: gait speed
This will be assessed by the T25FW [59] a quantitative
measure of gait speed, also included in the Multiple
Sclerosis Functional Composite. The patient is directed to
one end of a clearly marked 25-ft course and is instructed
to walk 25 ft (7.62 m) as quickly as possible, but safely,
using the prescribed assistive devices. The task is immedi-
ately administered again by having the patient walk back
the same distance. The test will be performed according to
the instructions reported on the manual of the National
Multiple Sclerosis Society. To ensure an accurate measure
of the primary outcome, the time needed for each subject
to complete the test will be collected with the aid of a
photocell system (Cronopics, Chronojump Boscosystem
Technologies, Rieti, Italy) with a precision of a millisecond
and simultaneously by the assessors with a chronometer.
Moreover, this test will always be performed as the first out-
come measure, to avoid possible muscle fatigue derived
Table 1 Schedule of enrollment, interventions and assessments
Abbreviations: T-1 enrollment, T0 baseline, T1 intermediate, T2 end of treatment, T3 3-month follow-up, EPC endothelial progenitor cell, CEC circulating endothelial
cells, T-reg immunological rare cell populations, ANGPT angiopoietin, BDNF Brain Derived Neurotrophic Factor, BMP Bone Morphogenetic Protein, dPAPP-A
Pregnancy-associated Plasma Protein A, EGF Epidermal Growth Factor, ET endothelin, FGF Fibroblast Growth Factor, FST follistatin, G- granulocyte, GM-
granulocyte-macrophage, CSF Colony Stimulating Factor, HB-EGF Heparin-binding EGF-like growth factor, HGF Hepatocyte Growth Factor, IFN interferon, IL
interleukin, ra receptor antagonist, IP-10 10 kDa-interferon gamma-induced protein, MCP-1 Monocyte Chemoattractant Protein 1, MIP-1α C-C motif chemokine 3,
MPO myeloperoxidase, NCAM Neural Cell Adhesion Molecule, PAI Plasminogen Activator Inhibitor, PDGF Platelet-derived Growth Factor, Pecam Platelet and
Endothelial Cell Adhesion Molecule, PLGF Placenta growth factor, PTX pentraxin, RANTES C-C motif chemokine ligand 5, sE-Selectin Soluble Endothelial Leukocyte
Adhesion Molecule, S-ICAM Soluble Intercellular Adhesion Molecule, s-VCAM Soluble Vascular Cell Adhesion Molecule, TF Tissue Factor, TNF Tumor Necrosis Factor,
VEGF Vascular Endothelial Growth Factor, GSH/GSSG reduced glutathione/oxidized glutathione ratio
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from the other test previously taken. The walking speed will
be calculated as the mean of the two trials performed.
Secondary outcome measures
A significant number of secondary outcome measures will
be employed to explore fatigue, QoL, balance, walking
endurance, mobility and their possible connection with
brain plasticity. Secondary outcomes will include: (1) clin-
ical measures and questionnaires, (2) hemodynamic and
metabolic evaluations and (3) laboratory-based measures.
Every specific measure is detailed in the following section.
Clinical and quality of life measures
1. 6-minute Walking Test (6MWT): walking endurance
is measured with the 6MWT. This test, first
validated in subjects with cardiopulmonary
problems, is also considered a feasible, reproducible
and reliable measure in MS [60]. Subjects will be
instructed to walk up and down as far as possible on
a 22-m walkway in 6 min without encouragement,
with the possibility to slow down and rest if
necessary. The total distance walked will be recorded
2. Berg Balance Scale: this is an assessment scale of
ability to maintain balance – statically or while
performing functional movement. It includes 14
observable tasks common to an everyday life
measured on a 5-point ordinal scale [61]. This scale
was previously widely employed in MS subjects [62]
3. Timed Up and Go test: the test is a combined
measure of gait speed, balance, coordination and
lower-limb strength. Subjects will be given verbal
instruction to stand up from a chair, walk 3 m at
their regular pace, cross a line marked on the floor,
turn around, walk back and sit down [63]. The
patients may use any gait aid that they normally use
during ambulation, but may not be assisted by
another person; however, a study staff member will
guard the subject during the test. Subjects will
perform three trials and the time it takes to perform
each trial will be recorded with a stopwatch.
The best trial will be considered
4. Fatigue Severity Scale: this is a method of evaluating
fatigue in MS and other conditions. Essentially, the
scale consists of answering a short questionnaire that
requires the subject to read each statement and rate
his or her level of fatigue from 1 to 7, depending on
how appropriate they felt the statement applied to
them over the preceding week [64]
5. Modified Ashworth Scale: this is a 6-point measure
of spasticity; the assessor will rate the perceived
amount of resistance or tone at the hip, knee and
ankle flexor and extensor muscles [56]
6. Patient Health Questionnaire: this is a questionnaire
to investigate the presence of depressive symptoms
as well as to characterize the severity of depression
[65]. It is composed of nine items based on the
frequency of occurrence in the past 2 weeks of
depression symptoms and has been found to be valid
also in individuals with MS [66]
7. Short Form Health Survey: this is a generic
measurement to measure health‐related QoL. It
consists of eight subscales with a score ranging from 0
to 100 used separately as outcome measures of
various aspects of health‐related QoL. It also
measures two main health concepts: physical and
mental. The questionnaire has been already employed
in clinical studies involving MS subjects [67]
8. Multiple Sclerosis Impact Scale: this is a 29‐item self‐
report measure with 20 items associated with a
physical scale and nine items with a psychological
scale [68]. Items ask about the impact of MS on
everyday life in the past 2 weeks with possible answers
set on a 1-to-5 Likert scale. Each of the two scales is
converted to a 0–100 scale where a score of 100
indicates a greater impact of disease on daily function
9. Multiple Sclerosis Walking Scale: this is a 12-item
walking scale that assesses a self-report measure of the
impact of MS on the individual’s walking ability [69]
Hemodynamic and metabolic evaluations
Complete brain circulation assessment will be performed
by the application of a validated model with parameters
measured at the bed side by the means of an Echo Color
Doppler. Subsequent post analysis permits us to obtain in-
flow and out-flow measurements as well as measurements
of the rate of collateral cerebral venous return [70]. Meta-
bolic measurements will be assisted by the NIRS technol-
ogy and by assessment of circulating metabolic marker
(refers to Laboratory-based measures section). NIRS is a
noninvasive, portable technique for the ambulatory,
remote monitoring of oxygenation changes in response to
motor tasks of human muscles and brain cortex. Patients
enrolled in the study will undergo metabolic evaluation
consisting of different measurements: assessment of mus-
cular oxygen consumption at gastrocnemius at rest
(rmVO2) and dynamic evaluation of cerebral activation
during a simple walking task performed on a treadmill.
Resting muscular oxygen consumption at gastrocnemius
The muscle metabolism assessment will be performed by a
continuous wave system (Oxymon MK III Artinis Medical
System, the Netherlands) consisting of two channels. The
measurement, already employed in MS subjects [71], is
performed on gastrocnemius in a resting supine position as
detailed elsewhere [72]. The absolute value of rmVO2 will
be measured in both legs and calculated by analyzing the
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rate of increase in deoxygenated hemoglobin concentration
during venous occlusion. The concentration changes of
deoxygenated hemoglobin will be converted into milliliters
of oxygen per 100 g of tissue per min. The mean value
between the two legs, as well as the data for the more
impaired leg, will be considered for data analysis.
Cerebral activation analysis during a motor task
The brain metabolism evaluation will be performed using
another optical imaging system (NIRScout, NIRx Medical
Technologies LLC, Glen Head, NY, USA) consisting of 16
light source fibers and 16 detector fibers, resulting in a
48-channel recording of cortical changes in oxygenated,
deoxygenated and total hemoglobin. For the measure-
ments of the present study the optodes will be tightly
placed on the skull with the use of a holder cap with the
interoptode distance set at 30 mm, covering the bilateral
motor and premotor cortex. Patients will walk on the
treadmill at a speed of 0.2 km/h assisted by personnel and
with partial body weight support if needed, performing
four short tasks (30 s of walking) alternated by rest periods
(30 s) [73]. Data will be analyzed for possible selective
changes of cerebral perfusion by specific software (NIR-
Slab). For each patient will be calculated the area under
the curve of oxygenated, deoxygenated and total
hemoglobin for each channel and hemisphere (media of
the area under curve of each one of the 24 channels of
selected hemisphere). Moreover, the data will also be ana-
lyzed with the software NIRS-SPM to draw a map of acti-
vation of the selected brain areas during the test and to
perform a t test statistical comparison within subjects and
between treatments, as well as other possible correlations
with clinical or laboratory parameters.
Laboratory-based measures
Samples processing (harvesting and storing)
Circulating biomarker analyses will be performed on blood
samples collected from patients at each time point (T0, T1,
T2 and T3), in fasting conditions, at the University Hospital
of Ferrara. Blood collection will consist of a total of
approximately 18 ml of whole blood distributed in three
different test tubes (based on the analyses to be performed)
containing either ethylenediaminetetraacetic acid (EDTA)
or sodium citrate or ribonucleic acid (RNA) stabilizer. Once
a suitable vein has been identified, the area where the nee-
dle will be inserted will be sterilized and the needle inserted.
When the amount of blood extracted satisfies the study
requests, the needle will be removed from the vein and a
swab will be placed on the forearm. The patient must
remain in a resting position for few minutes and they will
be asked to communicate any adverse reaction felt. The
blood samples collected will be labeled with a unique alpha-
numeric code identifying each participant; samples will be
then packed and safely transferred to the Biobank Service
of the Laboratories of the Technologies of the Advanced
Therapies of the University of Ferrara. Samples collected in
EDTA will be processed in real time for rare circulating cell
population quantification through multiparametric flow-
cytometry analyses. Samples collected in sodium citrate will
be centrifuged and plasma will be collected, aliquoted and
frozen at −80 °C in multiple and single-use aliquots for ana-
lysis of soluble circulating factors. Samples collected in
RNA stabilizer will be used for analysis of transcriptional
expression profiles. The biological samples of the partici-
pants will be catalogued and stored anonymously using the
unique alphanumeric code identifying the patients, the
access to samples will be restricted to the researchers
involved in the RAGTIME trial.
Blood samples analyses
 Circulating progenitor cell subsets, circulating
endothelial cells and immunological rare cell
populations (Treg) will be evaluated in fresh blood
collected in EDTA by multiparametric flow-cytometry
analyses [74, 75]
 Levels of glycolytic or mitochondrial activities will
be obtained by analysis of the metabolic markers
lactate and pyruvate and by the Glutathione Ratio.
These will be determined in plasma samples by
colorimetric assays [76–78]
 Cytokines/chemokines/growth factors, neurotrophic
factors, markers of brain damage and coagulation
factors will be quantified in plasma samples by
multiplex immunoassay according to the
manufacturer’s instructions by using specific
Milliplex MAP kits (Luminex xMAP technology,
Merck-Millipore, Germany) or by commercially
available enzyme-linked immunochemical and
immunosorbent assay following the manufacturing
instructions [76, 79, 80]
 Additional plasma proteins, encoded by RNA
selected by transcriptomic approaches [81], will be
measured in plasma samples by the above reported
assays
 Metabolism markers (lactate, pyruvate and
Glutathione Ratio) will be determined in plasma
samples by colorimetric assays [82]
Additional information is reported in Table 1.
Data management
The statistical unit will be responsible for data manage-
ment (quality control and data cleaning) and data analyses
according to the different research hypotheses described.
A statistician will be in charge for the analysis of clinical
and laboratory data, using several statistical packages such
as Medcalc Software (MedCalc Software bvba, Ostend,
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Belgium), IBM-SPSS Statistics (IBM, Armonk, NY, USA)
and Stata Statistical Software (Release 13. College Station,
TX: StataCorp LP, USA). Study design and statistical plan
of the study has been discussed with, and prepared by, the
supporting statistical unit working at our institution.
Sample size and power
The primary outcome for this study is to detect walking
differences (specifically, T25FW measurement) between
MS subjects who underwent RAGT and MS subjects
who underwent CT. To calculate the sample size for this
study, we used the data from a previous study [18]
where a RAGT effect size of 0.40 was observed. This
value is based on a decrease of values for T25FW from
8.8 ± 3.1 s at baseline to 7.4 ± 3.8 s after RAGT. Given
equal allocation between treatment and control arms, 88
subjects are required to maintain a Type I error rate of
5.0 and 80% power to detect a difference between inter-
vention groups. Conservatively, we expect a 10% rate of
dropout or loss to follow-up. We will assume that drop-
out participants will not improve from the last measured
point; thus, the sample size will be increased by 10% to
98 subjects (49 per arm).
Statistical analyses
Standard methods for the analysis of randomized controlled
trials will be employed. Firstly a comparison of baseline
characteristics of the two groups will be compared for
demographics, primary and secondary outcome measures.
Though our starting hypothesis called from a superiority of
RAGT with respect to CT, to allow for the chance that
participants enrolled in the CT group could have better
outcomes than those in the intervention arm, we will use
two-tailed tests of significance for all analyses. A p value of
0.05 will be considered statistically significant.
For the primary hypothesis, a two-way repeated meas-
ure analysis of variance (factors: treatment, time) will be
run to compare differences in gait speed within the
RAGT and CT groups at baseline, after treatment and
follow-up. Given the large number of planned secondary
outcomes, in order to reduce the probability of a false
positive result, for these specific analyses the significance
level will be fixed at 0.01.
Additional statistical analysis
The statistical significance of primary and secondary out-
come measures in score change between the groups will
be assessed using t tests for symmetrically distributed data
and analogous nonparametric tests, such as the Wilcoxon
signed-rank test, for data that are skewed. If a statistically
different distribution between the two groups in the base-
line outcome level is identified, a secondary analysis that
employs a multivariate modeling, such as analysis of
covariance, to adjust for these factors, will be performed.
Since MS encompass a wide spectrum of disabilities, the
general linear model will also analyze the effect of several
factors, so we will conduct exploratory analyses in which
we will include the MS onset (year) and EDSS subscores
(pyramidal function, cerebellar function and sensitive
functions) which define our MS in the model. Further-
more, the possible effects of disease-modifying or
symptom-modifying drugs (i.e., fampridine) on motor out-
come will be explored. Permutation tests may be imple-
mented to verify that valid p values will be obtained even
if model assumptions are not correct. Analysis of
hemodynamic, metabolic and laboratory-based measures
will be performed according to the procedures detailed
above. Possible correlation between these factors and
clinical measures will be assessed by Spearman’s rho or
included in multiple regression models.
Intention-to-treat
All analyses will be conducted using intention-to-treat,
where any subject randomized to one arm remains in that
arm regardless of whether or not they received the inter-
vention. Missing values, though we will make any effort
possible to reduce their incidence, will be treated using
the multiple imputation procedure, considered one of the
best methods to handle missing data [83]. Moreover, a
sensitivity analysis that assesses the stability of the study’s
conclusions, comparing intention-to-treat analysis to an
analysis that takes into account level of participation in
the intervention arm, will also be performed.
Data monitoring and interim analysis
The RAGTIME trial, dealing with well-established and
safe rehabilitation procedures, paralleled by a rigorous
handling of potential harms as a local hospital policy, ex-
pects to minimize all the potential risks. Moreover, this
being a single-center study, a Data Monitoring Commit-
tee will not be required. The research coordinator will
be in charge of the interim analysis (with statistician
support) and for taking the final decision to stop, modify
or terminate the trial. Eventual possible modifications or
amendments to the protocol will be discussed within the
research group and communicated by the research
coordinator to the funding body for approval or refusal.
An interim analyses performed by the scientific experts
of the funding body will be scheduled after 18 months
from the beginning of the trial. It will consist of a com-
pilation of an interim evaluation checklist form, of a
study interim report form and a public preliminary data
presentation and discussion. Once the trial is concluded,
the research coordinator will be responsible for the final
dataset, and will state the number of research team
members who can have access to the data collected.
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Dissemination plan
The results derived from this trial will be published in
high-quality journals and presented at national and inter-
national meetings. The results will also be disseminated
through conferences organized by the funding agency,
Regione Emilia Romagna. The authors also intend to
spread the information learned from this project by pre-
senting it at MS support groups, to inform the patients
about the efficacy of one or the other treatment and the
local availability of them.
Discussion
The study may provide significant information on the
rehabilitation of severely disabled, progressive MS pa-
tients, clarifying the possible application of technologies
in clinical practice with a high number of participants
with a limited range of disability; thus, reducing the bias
present in the previous studies.
From the proposed trial, we expect to observe a greater
effect of high-intensive robotic rehabilitation on mobility
and functional recovery in a large cohort of MS patients
compared to CT. Functional recovery after rehabilitation
programs has to be considered a multifactorial process in
which integrated and multicomponent biological systems
are implicated, i.e., vascular, neuronal and metabolic.
Quantity (duration and frequency) and quality (task-speci-
ficity) of interventions are appropriate to facilitate
enhanced neural reorganization and motor recovery,
favoring adaptations in the adult brain. Cortical adaptive
changes could, therefore, contribute to functional recovery
from lesions and may have an important role in compen-
sating for axonal injury in MS. Therefore, following the
intervention or during the different phases of intensive
rehabilitation, we expect to detect possible modulation of
biomarkers of brain plasticity related to cortical activation
and/or of circulating regenerative markers, potentially cor-
related with the clinical outcomes. Our findings will help
to identify specific markers to detect whether a patient
should be a “responder” to a rehabilitative intervention,
bearing in mind that due to a wide variety of symptoms,
the rehabilitation process in persons with MS is multifac-
torial and should always be tailored to patient characteris-
tics. Moreover, this study might increase knowledge on
the effects of MS gait rehabilitation, leading to an
optimization of health care resources and developing cost-
effective rehabilitation programs. Lastly, from a scientific
point of view, the study represents a step towards the
knowledge of the functional reorganization processes in
progressive MS patients, identifying the effectiveness of
intensive rehabilitative interventions through the changes
of clinical and circulating biomarkers of MS plasticity.
However, further studies will be necessary to confirm the
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